Search Results - "Chamai, M"

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial by Thompson, Jennifer A, Kityo, Cissy, Dunn, David, Hoppe, Anne, Ndashimye, Emmanuel, Hakim, James, Kambugu, Andrew, van Oosterhout, Joep J, Arribas, Jose, Mugyenyi, Peter, Walker, A Sarah, Paton, Nicholas I

“…Abstract Background Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment programs in low-income countries often delays detection of…”
Get full text

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial by Thompson, Jennifer, Kityo, Cissy, Kambugu, Andrew, Lugemwa, Abbas, Mwebaze, Raymond, Thomason, Margaret J, Mugyenyi, Peter, Walker, A Sarah, Bakeinyaga, G, Kasuswa, S, Mulima, D, Musana, H, Namata, H, Nkalubo, J, Okello, P, Pimundu, G, Segonga, P, Ssali, F, Kayiwa, J, Tukamushaba, J, Abunyang, S, Lwalanda, R, Namusanje, J, Katwere, M, Komujuni, C, Matovu, J, Nakajubi, A, Nalumenya, R, Semitala, F, Ssenkindu, T, Acaku, M, Ssebutinde, P, Kukundakwe, J, Naluguza, M, Nsibuka, F, Fortunate, M, Acen, J, Achidri, J, Chamai, M, Kiconco, M, Matama, C, Nambaziira, F, Rweyora, A, Tumwebaze, G, Kiyingi, A, Senoga, I, Abwola, M, Mudoola, M, Ssennono, F, Amone, G, Arach, B, Bekusike, G, Bulegyeya, A, Nassali, A, Ndukukire, Ntawiha, H, Rogers, A, Kiirya, S, Balmoi, F, Kafuma, S, Phiri, M, Mudzingwa, S, Bafana, T, Chitongo, S, Lifa, Linly, Musowa, George, Mwimaniwa, Grace, Sikwese, Rosemary, Ziwoya, Milton, Kamanga, S, Makwakwa, T Kayinga E, Mlenga, M, Mphande, T, Mtika, C, Nyirenda, R, Mudogo, A, Wools-Kaloustian, K, Kunda, I, Mufwambi, W, Mulenga, L, Namfukwe, M, Kerukadho, E, Ngwatu, B, Tebbs, S, Whittle, J, Wilkes, H, Kyomuhendo, F, Mkandawire, N, Senyonjo, S, Angus, B, Palfreeman, A, Arribas, J, Floridia, M, Walsh, P, De Rosa, M, Gilks, C, Kangewende, A, van Wyk, J, Lehrman, S, Rooney, J

“…Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines…”
Get full text

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial by Paton, Nicholas I, Prof, Kityo, Cissy, MSc, Thompson, Jennifer, MSc, Nankya, Immaculate, PhD, Bagenda, Leonard, MMD, Hoppe, Anne, PhD, Hakim, James, Prof, Kambugu, Andrew, MMed, van Oosterhout, Joep J, PhD, Kiconco, Mary, MPH, Bertagnolio, Silvia, MD, Easterbrook, Philippa J, MD, Mugyenyi, Peter, Prof, Walker, A Sarah, Prof

“…Summary Background Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase…”
Get full text

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index by Shi, Yuan, Thompson, Jennifer, Walker, A Sarah, Paton, Nicholas I, Cheung, Yin Bun

“…Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to…”
Get full text

HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa by Hoppe, Anne, Giuliano, Marina, Lugemwa, Abbas, Thompson, Jennifer A, Floridia, Marco, Walker, Ann S, Senoga, Ismail, Abwola, Mary C, Pirillo, Maria F, Kityo, Cissy M, Arenas-Pinto, Alejandro, Paton, Nicholas I

“…HIV is transmitted primarily through sexual intercourse, and the objective of this study was therefore to assess whether there is occult viral replication and…”
Get more information